Inhibition of gastric motility and gastric acid secretion following treatment with GLP-1R agonists has been demonstrated in mice [792], rats [[793], [794], [795]], dogs [[796], [797], [798]], pigs [799,800], and humans [573,[789], [790], [791],799,[801], [802], [803], [804], [805]]
Many patients with diabetes have overlapping cardiovascular and renal complications that require coordinated treatment strategies
By stimulating insulin secretion in response to elevated blood glucose levels, GLP-1 therapies help lower blood sugar levels
10.1007/BF02172145 45
GLP-1RAs are found to modulate immune cell signaling by cAMP/PI3K-AKT and regulate NF-B as the crucial inflammation controller [159,204]
Consider in Differential Diagnosis: When a patient on a GLP-1 or GIP/GLP-1 medication presents with new-onset neuropathic pain or sensory abnormalities, consider the medication as a potential cause